Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Mr. John Dawson

Market Cap

412.01 Million GBp

Sector

Healthcare

Website

https://www.oxb.com

Description

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally.

Read More

Overview

Value

2

Growth

61

Health

65

Management

79

Analyst Opinion

69

Total

55

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Has a low level of debt
  • Has strong financial health
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings growth has slowed down recently
  • Income is not covering expenditure and investment
  • There is a history of diluting shareholders
  • No margin of safety at their current market price

Market Peers

OXB.L

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-99.45%

Revenue Growth (5 Year Average)

21.94%

Ratings Consensus

Buy

Share Buybacks

-17.18%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

2

  • Estimated intrinsic-value of 2.37 GBp is lower than current price ( 428.00 GBp)
  • Free-cashflow-yeild of -0.05% is worse than the market average (4.7%)
  • Margin-of-safety of -99.45% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 428 GBp

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-0.05%

PE/Earnings Growth

N/A

Price/Book

15845.72x

Growth

Growth Score

61

  • 5 Year Average Revenue growth of 21.94% is higher than the market average (10.97%)
  • Revenue growth has slowed this year
  • 5 Year Average Earnings growth of 12.25% is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of 12.25% is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

21.94%

Earnings Growth

12.25%

Cashflow Growth

12.25%

Health

Health Score

65

  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow
  • Cashflow is negative

Altman Z Score

N/A

Piostroski Score

N/A

Debt/Equity

0.05x

Current Assets/Liabilities

4.92x

Free Cashflow/Total Debt

1.71x

Debt/Capital

0.06x

Management

Management Score

79

  • Has issued new shares to finance growth when share price is high
  • Return-on-equity of 931.26% is higher than the market average (15%)
  • Return-on-capital-employed of 16.88% is higher than the market average (10%)
  • Has a history of diluting shareholders to finance activity

Average Buybacks/Dilution

-17.18%

Recent Buybacks/Dilution

N/A

5 Year Price Volitility

31.89%

Return On Assets

735.41%

Return On Capital Employed

16.88%

Return On Equity

931.26%

Return On Free Cashflow

-17033.88%

Return On Investments

N/A

Analysts

Analyst Opinion

69

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Oxford Biomedica plc

Currency

GBp

Beta

1.031764

Vol Avg

153807

Ceo

Mr. John Dawson

Cik

Cusip

G6836F189

Exchange

London Stock Exchange

Full Time Employees

959

Industry

Biotechnology

Sector

Healthcare

Ipo Date

1996-11-15

Address

Windrush Court, Transport Way

City

Oxford

State

OXFORDSHIRE

Country

GB

Zip

OX4 6LT

Phone

441865783000

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies